{
  "Best_Efforts": {
    "regulatory_efforts": [
      {
        "section": "Best_Efforts",
        "field_name": "effort_standard",
        "answer": "Reasonable Best Efforts",
        "confidence": 0.9,
        "reason": "The clause explicitly states that the parties will use 'reasonable best efforts' to obtain regulatory approvals and satisfy conditions for the merger, which is a standard M&A term indicating a high level of effort short of 'Hell or High Water.'",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "effort_scope",
        "answer": "RBE for HSR and other applicable Antitrust Laws",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "regulatory_fillings_hsr": [
      {
        "section": "Best_Efforts",
        "field_name": "hsr_required",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "hsr_filing_deadline_days",
        "answer": 25,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "hsr_notes",
        "answer": "Each party shall make its respective filings under the HSR Act no later than twenty-five (25) Business Days following the date of this Agreement; expiration or early termination of the waiting period under the HSR Act is a condition to closing.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "regulatory_fillings_cfiius": [
      {
        "section": "Best_Efforts",
        "field_name": "cfiius_required",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "cfiius_filing_deadline_days",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "cfiius_notes",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "regulatory_fillings_foreign": [
      {
        "section": "Best_Efforts",
        "field_name": "foreign_notes",
        "answer": "Foreign filings may be required under applicable non-U.S. laws",
        "confidence": 0.9,
        "reason": "The agreement mentions the need for filings under 'other applicable Antitrust Laws,' which implies that foreign antitrust or merger control filings may be necessary.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "foreign_required",
        "answer": true,
        "confidence": 0.9,
        "reason": "The agreement references obligations under 'other applicable Antitrust Laws' in Section 5.4, which implies that foreign filings are required.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "foreign_filing_deadline_days",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "divestiture_commitments": [
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_required",
        "answer": true,
        "confidence": 0.9,
        "reason": "Section 5.4(d) explicitly mentions that Parent, Merger Sub, and Parent's Subsidiaries shall take all actions necessary to eliminate impediments under any Antitrust Law, including agreeing to Remedy Actions such as divestiture, hold-separate arrangements, or other commitments to secure regulatory approval, with certain limitations.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_target_value",
        "answer": 140,
        "confidence": 0.9,
        "reason": "The agreement specifies that Parent and its Subsidiaries are not required to take Remedy Actions with respect to businesses and products of the Company and its Subsidiaries that generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_target_unit",
        "answer": "USD_millions",
        "confidence": 0.9,
        "reason": "The clause specifies a divestiture cap based on net sales exceeding $140,000,000 during the Company's 2024 fiscal year, which is a financial measure expressed in dollar value.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_target_basis",
        "answer": "revenue",
        "confidence": 0.9,
        "reason": "The divestiture cap is measured against 'net sales', which is functionally equivalent to 'revenue'.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_target_basis_scope",
        "answer": "Target",
        "confidence": 0.8,
        "reason": "The divestiture cap is applied to businesses and products of the Company and its Subsidiaries, as indicated by the reference to net sales generated by the Company and its Subsidiaries in the fiscal year.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_target_notes",
        "answer": "Cap applies to Target units generating more than $140,000,000 in net sales during the Company's 2024 fiscal year.",
        "confidence": 0.9,
        "reason": "The clause in Section 5.4(d) specifies that Parent and its Subsidiaries are not required to take Remedy Actions with respect to businesses and products of the Company that generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year, implying a divestiture cap based on sales.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_target_clause_reference",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_buyer_value",
        "answer": 140000000,
        "confidence": 0.9,
        "reason": "The agreement specifies that Parent and its Subsidiaries are not required to take Remedy Actions with respect to businesses and products of the Company and its Subsidiaries that generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year, implying a divestiture cap at this value.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_buyer_unit",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_buyer_basis",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_buyer_basis_scope",
        "answer": "Parent",
        "confidence": 0.9,
        "reason": "The divestiture commitments section implies that the divestiture cap applies to Parent and its Subsidiaries, as it refers to actions required by Parent and its Subsidiaries to comply with antitrust laws, which typically involve divestitures.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_buyer_notes",
        "answer": "Parent and its Subsidiaries shall not be required to agree to, commit to, proffer, propose or take any Remedy Actions with respect to any businesses and products of Parent and its Subsidiaries (other than, following the Closing, and subject to certain conditions, the Company and its Subsidiaries).",
        "confidence": 0.9,
        "reason": "The clause specifies that Parent is not required to take Remedy Actions with respect to its own businesses and products, implying a limitation on divestiture commitments.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_cap_buyer_clause_reference",
        "answer": "Section 5.4(d)",
        "confidence": 0.9,
        "reason": "The section outlines the obligations of Parent, Merger Sub, and Parent's Subsidiaries to take actions necessary to eliminate impediments under Antitrust Law, which includes divestiture commitments.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_scope_exclusions",
        "answer": [
          "businesses and products of the Company and its Subsidiaries that individually or in the aggregate, generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year",
          "businesses and products of Parent and its Subsidiaries (other than, following the Closing, and subject to the preceding clause, the Company and its Subsidiaries)"
        ],
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_clause_summary",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "divestiture_clause_summary_clause_reference",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "litigation_commitments": [
      {
        "section": "Best_Efforts",
        "field_name": "litigation_requirement_status",
        "answer": "Explicit Requirement to Litigate",
        "confidence": 0.9,
        "reason": "Section 5.4(d) requires Parent to defend through litigation any Proceeding that seeks to prevent, prohibit, interfere with, or delay the Closing, implying a duty to litigate to secure closing.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "litigation_clause_scope",
        "answer": "Litigate through appeals to eliminate impediments under Antitrust Law and obtain necessary consents unless Remedy Actions exceed specified thresholds.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "required_to_litigate_notes",
        "answer": "Parent must litigate regulatory challenges, including appeals, unless conditions to closing are impossible.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "withdrawal_and_timing_controls_withdrawal": [
      {
        "section": "Best_Efforts",
        "field_name": "withdrawal_control_type",
        "answer": "mutual_consent_required",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "withdrawal_control_type_notes",
        "answer": "Neither the Company nor Parent will withdraw any such filings or applications without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned or delayed.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "withdrawal_and_timing_controls_timing": [
      {
        "section": "Best_Efforts",
        "field_name": "timing_agreement_restriction",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "timing_agreement_restriction_notes",
        "answer": "Neither the Company nor Parent will withdraw any such filings or applications without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned or delayed. None of Parent, Merger Sub or the Company (including their respective Subsidiaries) shall, without the other party's prior written consent, enter into any timing or similar agreement, or otherwise agree or commit to any arrangement, that would have the effect of extending, suspending, lengthening or otherwise tolling the expiration or termination of any waiting period applicable to consummate the transactions contemplated by this Agreement under the HSR Act, such consent not to be unreasonably withheld, conditioned or delayed.",
        "confidence": 0.9,
        "reason": "The clause specifies consent requirements and restrictions on modifying waiting periods under the HSR Act, which aligns with the timing agreement restriction notes.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "remedy_actions_other": [
      {
        "section": "Best_Efforts",
        "field_name": "remedy_definitions_provided",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "remedy_definition_text",
        "answer": "Divest, license, or take steps to satisfy regulator",
        "confidence": 0.9,
        "reason": "The term 'Remedy Action' is defined in Section 5.4(d) as actions required to sell, divest, hold separate, lease, license, transfer, dispose of or otherwise encumber or impair assets to eliminate impediments under Antitrust Law.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "remedy_definition_text_clause_reference",
        "answer": "Section 5.4(d)",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "transaction_interference": [
      {
        "section": "Best_Efforts",
        "field_name": "restriction_on_other_transactions",
        "answer": true,
        "confidence": 0.9,
        "reason": "The agreement includes restrictions on the Company from soliciting or pursuing alternative transactions that could interfere with the merger, as indicated by language prohibiting actions that would lead to an Acquisition Proposal and requiring termination of existing discussions with third parties.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "interference_clause_text",
        "answer": "sell, divest, hold separate, lease, license, transfer, dispose of or otherwise encumber or impair or take any other action with respect to the Company's or any of their respective Affiliate's assets, properties, businesses or product lines",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "interference_clause_text_clause_reference",
        "answer": "Section 5.4",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "second_request_certification": [
      {
        "section": "Best_Efforts",
        "field_name": "deadline_specified",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "certification_timeline_notes",
        "answer": "Each of the parties hereto shall, in consultation and cooperation with the other parties and as promptly as reasonably practicable, but in any event no later than twenty-five (25) Business Days following the date of this Agreement, make its respective filings under the HSR Act, and make any other applications and filings as reasonably determined by the Company and Parent under other applicable Antitrust Laws with respect to the transactions contemplated by this Agreement, as promptly as practicable, but in no event later than as required by Law.",
        "confidence": 0.9,
        "reason": "The timeline for certifying compliance with a Second Request under the HSR Act is implied by the requirement to make filings under the HSR Act within 25 business days of the agreement date.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "certification_responsibility_party",
        "answer": "Both",
        "confidence": 0.9,
        "reason": "The agreement requires both parties to cooperate and use reasonable best efforts to make filings under the HSR Act, implying joint responsibility for certifying compliance.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "ftc_warning_letter_handling": [
      {
        "section": "Best_Efforts",
        "field_name": "addressed",
        "answer": "false",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "handling_notes",
        "answer": "Not addressed",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "effect_on_closing_condition",
        "answer": "Silent",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "addressed_notes",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "other_timing_controls": [
      {
        "section": "Best_Efforts",
        "field_name": "other_deadlines_specified",
        "answer": [
          "Company Stockholders' Meeting to occur within 50 days of Form F-4 effectiveness",
          "Adjournments or postponements of the Company Stockholders' Meeting without Parent's consent shall be for a period of no more than 25 Business Days in the aggregate"
        ],
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "novel_or_unstructured_regulatory_clauses": [
      {
        "section": "Best_Efforts",
        "field_name": "items",
        "answer": [
          {
            "summary": "Neither the Company nor Parent will withdraw any filings or applications without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned, or delayed.",
            "section": "Section 5.4(a)",
            "review_required": true
          },
          {
            "summary": "None of Parent, Merger Sub, or the Company shall, without the other party's prior written consent, enter into any timing or similar agreement, or otherwise agree or commit to any arrangement, that would have the effect of extending, suspending, lengthening, or otherwise tolling the expiration or termination of any waiting period applicable to consummate the transactions under the HSR Act.",
            "section": "Section 5.4(a)",
            "review_required": true
          },
          {
            "summary": "Neither Parent nor any of its Affiliates shall be required to, and without the prior written consent of Parent, none of the Company or any of its Subsidiaries or Affiliates will, grant or offer to grant any accommodation or concession (financial or otherwise), or make any payment, to any third party (other than filing fees to any Governmental Authority), in connection with seeking or obtaining its consent to the transactions.",
            "section": "Section 5.4(a)",
            "review_required": true
          },
          {
            "summary": "Parent and its Subsidiaries shall not be required to agree to, commit to, proffer, propose, or take any Remedy Actions with respect to any businesses and products of the Company and its Subsidiaries that generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year.",
            "section": "Section 5.4(d)",
            "review_required": true
          },
          {
            "summary": "The Company shall not, without Parent's prior written consent, agree to, commit to, proffer, propose, or take Remedy Actions.",
            "section": "Section 5.4(d)",
            "review_required": true
          },
          {
            "summary": "No party shall be required to agree to, commit to, proffer, propose, or take Remedy Actions unless they are conditioned upon the consummation of the transactions.",
            "section": "Section 5.4(d)",
            "review_required": true
          }
        ],
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "prior_approval_commitment": [
      {
        "section": "Best_Efforts",
        "field_name": "addressed",
        "answer": "false",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "obligations_summary",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "clause_reference",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "regulatory_process_control_discretion": [
      {
        "section": "Best_Efforts",
        "field_name": "regulatory_process_control_discretion",
        "answer": "Joint, mutual consent required",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "parent_has_sole_discretion_excluding_remedies",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "no_limitations_on_buyer_remedies": [
      {
        "section": "Best_Efforts",
        "field_name": "value",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "inferred_hohw",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "explanation",
        "answer": "Not applicable",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "notes",
        "answer": "Parent and its Subsidiaries shall not be required to take Remedy Actions with respect to any businesses and products of the Company and its Subsidiaries that generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year.",
        "confidence": 0.9,
        "reason": "The clause in Section 5.4(d) specifies a threshold for Remedy Actions related to divestitures or other actions concerning businesses and products with net sales exceeding $140,000,000.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "inferred_hohw_notes",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "materiality_basis",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "materiality_definition_text",
        "answer": "Parent and its Subsidiaries shall not be required to agree to, commit to, proffer, propose or take any Remedy Actions with respect to any businesses and products of the Company and its Subsidiaries that individually or in the aggregate, generated net sales in excess of $140,000,000 during the Company's 2024 fiscal year.",
        "confidence": 0.9,
        "reason": "The clause in Section 5.4(d) specifies a financial threshold for Remedy Actions, indicating that the Buyer is not required to take actions affecting businesses with net sales exceeding $140 million.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ],
    "refiling_commitment": [
      {
        "section": "Best_Efforts",
        "field_name": "refiling_commitment_required",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "refiling_commitment_required_notes",
        "answer": "Neither the Company nor Parent will withdraw any such filings or applications without the prior written consent of the other party, such consent not to be unreasonably withheld, conditioned or delayed.",
        "confidence": 0.9,
        "reason": "The clause specifies that neither party can withdraw filings without the other's consent, which implies a commitment to refile if necessary to obtain clearance.",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "refiling_commitment_max_refiles",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "refiling_commitment_max_refiles_notes",
        "answer": "Not Specified",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "refiling_commitment_max_refiles_specification_status",
        "answer": "Not Specified",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      },
      {
        "section": "Best_Efforts",
        "field_name": "refiling_commitment_clause_reference",
        "answer": "Section 5.4",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Efforts",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Financing Cooperation"
        ]
      }
    ]
  },
  "Conditions to Closing": [
    {
      "section": "Conditions to Closing",
      "field_name": "mutual_conditions_list",
      "answer": [
        "The Company shall have obtained the Company Stockholder Approval.",
        "The Parent Share Issuance shall have been approved for listing on the NYSE, subject to official notice of issuance.",
        "The Form F-4 shall have become effective under the Securities Act and shall not be the subject of any stop order or any Proceedings by or before the SEC seeking a stop order.",
        "Any applicable waiting period (and any extension thereof) under the HSR Act relating to the consummation of the Merger shall have expired or early termination thereof shall have been granted (the 'Required Regulatory Approval').",
        "No Governmental Authority of competent jurisdiction shall have issued or entered any Order after the date of this Agreement, and no Law shall have been enacted or promulgated after the date of this Agreement, in each case, that (whether temporary or permanent) is then in effect and has the effect of enjoining or otherwise prohibiting the consummation of the Merger (a 'Restraint')."
      ],
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  General and Mutual Conditions",
        "Covenants  >  Efforts",
        "The Merger  >  Effective Time & Closing Process"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "parent_closing_conditions",
      "answer": [
        "The representations and warranties of the Company contained in specified sections must be true and correct in all respects or in all material respects as of the Closing Date, except for de minimis inaccuracies or where failure to be true and correct would not have a Material Adverse Effect on the Company.",
        "The Company must have performed or complied in all material respects with its obligations required under the Agreement to be performed or complied with on or prior to the Closing.",
        "Since the date of the Agreement, there must not have been any event, circumstance, occurrence, effect, fact, development, or change that has had, or would reasonably be expected to have, a Material Adverse Effect on the Company.",
        "Parent must have received a certificate signed by an executive officer of the Company certifying as to the matters set forth in the conditions regarding representations and warranties, compliance with obligations, and absence of a Material Adverse Effect on the Company."
      ],
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Covenants  >  Efforts",
        "The Merger  >  Closing Deliverables"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "company_closing_conditions",
      "answer": [
        "Representations and warranties of Parent and Merger Sub must be true and correct in all respects or in all material respects as applicable.",
        "Parent and Merger Sub must have performed or complied in all material respects with their obligations under the Agreement.",
        "No Material Adverse Effect on Parent since the date of the Agreement.",
        "Receipt of a certificate signed by an executive officer of Parent certifying compliance with the conditions."
      ],
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Covenants  >  Efforts",
        "The Merger  >  Closing Deliverables"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "target_shareholder_approval_required",
      "answer": true,
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Covenants  >  Shareholder Vote/Meeting",
        "The Merger  >  Shareholder Vote Mechanics"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "target_shareholder_approval_threshold",
      "answer": "majority of the outstanding shares of Company Common Stock entitled to vote thereon",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Covenants  >  Shareholder Vote/Meeting",
        "The Merger  >  Shareholder Vote Mechanics"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "hsr_clearance_required",
      "answer": "(d) any applicable waiting period (and any extension thereof) under the HSR Act relating to the consummation of the Merger shall have expired or early termination thereof shall have been granted (the \"Required Regulatory Approval\");",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  General and Mutual Conditions",
        "Covenants  >  Efforts",
        "The Merger  >  Effective Time & Closing Process"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "other_customary_conditions",
      "answer": [
        "Company Stockholder Approval obtained",
        "Parent Share Issuance approved for listing on the NYSE",
        "Form F-4 effective under the Securities Act and not subject to stop order",
        "Expiration or early termination of waiting period under the HSR Act",
        "No Governmental Authority issued an Order prohibiting the Merger"
      ],
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  General and Mutual Conditions",
        "Covenants  >  Efforts",
        "The Merger  >  Closing Deliverables"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "financial_conditions_minimum_cash_threshold",
      "answer": "Not found",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Financing Provisions  >  Purchase Price Allocation",
        "Financing Provisions  >  Financial Statement Delivery"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "financial_conditions_maximum_net_debt",
      "answer": "Not found",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Financing Provisions  >  Purchase Price Allocation",
        "Financing Provisions  >  Financial Statement Delivery"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "financial_conditions_minimum_any_condition",
      "answer": "Not found",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Financing Provisions  >  Purchase Price Allocation",
        "Financing Provisions  >  Financial Statement Delivery"
      ]
    },
    {
      "section": "Conditions to Closing",
      "field_name": "tax_conditions_tax_opinion_required",
      "answer": "Not found",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Conditions to Closing  >  Party-Specific Conditions",
        "Covenants  >  Tax Matters",
        "The Merger  >  Deal Structure"
      ]
    }
  ],
  "material_adverse_effect": {
    "mae_carveout": [
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_general_economic_conditions_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_general_economic_conditions_explanation",
        "answer": "changes in general economic, financial market, regulatory, business, financial, political, geopolitical, credit or capital market conditions, including interest or exchange rates, tariffs and trade wars",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_industry_conditions_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_industry_conditions_explanation",
        "answer": "changes or developments in any of the industries or markets in which such Person or any of its Subsidiaries operate",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_stock_price_changes_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_stock_price_changes_explanation",
        "answer": "Any change in the price or trading volume of such Person's securities or other financial instruments or change in such Person's credit rating, in and of itself (provided that the facts or occurrences giving rise to or contributing to such change that are not otherwise excluded from the definition of 'Material Adverse Effect' may constitute or be taken into account in determining whether a Material Adverse Effect has occurred)",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_credit_rating_changes_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_credit_rating_changes_explanation",
        "answer": "Any change in the price or trading volume of such Person's securities or other financial instruments or change in such Person's credit rating, in and of itself, is excluded from constituting a Material Adverse Effect, provided that the facts or occurrences giving rise to or contributing to such change that are not otherwise excluded may be considered in determining a Material Adverse Effect.",
        "confidence": 0.9,
        "reason": "The clause explicitly excludes changes in credit ratings from being considered a Material Adverse Effect, unless the underlying causes are not otherwise excluded.",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_legal_or_regulatory_changes_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_legal_or_regulatory_changes_explanation",
        "answer": "changes in general economic, financial market, regulatory, business, financial, political, geopolitical, credit or capital market conditions, including interest or exchange rates, tariffs and trade wars; (ii) general changes or developments in any of the industries or markets in which such Person or any of its Subsidiaries operate; (iii) (A) adoption, implementation, repeal, modification or amendment of any applicable Laws or (B) changes in GAAP, or in the case of each of clause (A) and (B), any proposal therefor or change in interpretations or enforcement thereof",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_force_majeure_events_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_force_majeure_events_explanation",
        "answer": "acts of war (whether or not declared), hostilities, military actions or acts of terrorism, cyberterrorism (to the extent not specifically targeting such Person), or any escalation or worsening of the foregoing, weather related events, fires, natural disasters, epidemics, pandemics, plagues or other outbreaks of illness or disease or public health events (including COVID-19) or any other acts of God",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_political_events_or_war_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_political_events_or_war_explanation",
        "answer": "acts of war (whether or not declared), hostilities, military actions or acts of terrorism, cyberterrorism (to the extent not specifically targeting such Person), or any escalation or worsening of the foregoing",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_pandemic_health_events_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_pandemic_health_events_explanation",
        "answer": "Material Adverse Effect shall mean, with respect to Parent or the Company, any event, circumstance, occurrence, effect, fact, development or change that, individually or in the aggregate, has a material adverse effect on the business, financial condition or results of operations of such Person and its Subsidiaries, taken as a whole; provided that none of the following (or the results thereof) shall constitute or be taken into account in determining whether a Material Adverse Effect shall have occurred: ... (vi) acts of war (whether or not declared), hostilities, military actions or acts of terrorism, cyberterrorism (to the extent not specifically targeting such Person), or any escalation or worsening of the foregoing, weather related events, fires, natural disasters, epidemics, pandemics, plagues or other outbreaks of illness or disease or public health events (including COVID-19) or any other acts of God;",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_agreement_compliance_effects_included",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_agreement_compliance_effects_explanation",
        "answer": "The definition of Material Adverse Effect includes a carve-out for effects resulting from the execution of this Agreement, the public announcement, pendency or consummation of the Merger or the other transactions contemplated by this Agreement, including any effect on relationships with customers, suppliers, or employees.",
        "confidence": 0.9,
        "reason": "The clause explicitly excludes effects resulting from the execution, announcement, or consummation of the merger from being considered a Material Adverse Effect.",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_parent_actions_included",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_parent_actions_explanation",
        "answer": "Any action taken or not taken at the express written request of the Company (in the case of Parent) or Parent (in the case of the Company) after the date of this Agreement shall not constitute a Material Adverse Effect.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that actions taken or not taken at the express written request of the other party are excluded from the definition of Material Adverse Effect.",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_projections_miss_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_projections_miss_explanation",
        "answer": "any failure by such Person to meet its internal or published projections, budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operation or any published analyst or other third-party estimates or expectations of such Person's revenue, earnings or other financial performance or results of operations for any period, in and of itself (provided that the facts or occurrences giving rise to or contributing to such failure that are not otherwise excluded from the definition of 'Material Adverse Effect' may constitute or be taken into account in determining whether a Material Adverse Effect has occurred)",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_other_custom_items_present",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Conduct of Business",
          "Termination  >  Other Termination Rights"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveout_other_custom_items",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  ESG & Sustainability",
          "Covenants  >  Transaction Litigation"
        ]
      }
    ],
    "mae_carveback": [
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_disproportionate_effects_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_disproportionate_effects_explanation",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_additional_exceptions_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_additional_exceptions_explanation",
        "answer": "The exceptions in clauses (i) through (iii) and (vi) shall not apply to the extent the events, circumstances, occurrences, effects, facts, developments or changes set forth in such clauses have a disproportionate impact on such Person and its Subsidiaries, taken as a whole, relative to the other participants in the industries in which such Person and its Subsidiaries operate.",
        "confidence": 0.9,
        "reason": "The clause specifies that certain carve-outs do not apply if the events have a disproportionate impact, which is a scenario-based trigger for reintroducing carve-outs.",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_causation_based_analysis_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      },
      {
        "section": "material_adverse_effect",
        "field_name": "mae_carveback_causation_based_analysis_explanation",
        "answer": "The clause provides that changes in the price or trading volume of a Person's securities or other financial instruments, or changes in a Person's credit rating, in and of themselves, do not constitute a Material Adverse Effect. However, the facts or occurrences giving rise to or contributing to such changes that are not otherwise excluded from the definition of 'Material Adverse Effect' may be considered in determining whether a Material Adverse Effect has occurred.",
        "confidence": 0.9,
        "reason": "The clause explicitly states that while certain events are excluded from being considered a Material Adverse Effect, the underlying causes of those events can still be considered if they are not otherwise excluded.",
        "categories_used": [
          "Definitions  >  Material Adverse Effects",
          "Covenants  >  Efforts",
          "Covenants  >  Transaction Litigation"
        ]
      }
    ]
  },
  "Merger_Agreement_Details": [
    {
      "section": "Merger_Agreement_Details",
      "field_name": "deal_name",
      "answer": "The AZEK Company Inc.",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Preamble  >  Preamble",
        "Definitions  >  Material Adverse Effects",
        "Representations & Warranties  >  By the Target"
      ]
    },
    {
      "section": "Merger_Agreement_Details",
      "field_name": "termination_fee",
      "answer": "272000000",
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Termination  >  Termination Fee",
        "Covenants  >  Deal Protection",
        "Financing Provisions  >  Debt Financing"
      ]
    },
    {
      "section": "Merger_Agreement_Details",
      "field_name": "reverse_termination_fee",
      "answer": 272000000,
      "confidence": 1.0,
      "reason": "",
      "categories_used": [
        "Termination  >  Termination Fee",
        "Covenants  >  Deal Protection",
        "Miscellaneous  >  Legal Enforcement"
      ]
    },
    {
      "section": "Merger_Agreement_Details",
      "field_name": "outside_date",
      "answer": "12-month anniversary of the date of this Agreement",
      "confidence": 0.9,
      "reason": "The Termination Date is specified as the 12-month anniversary of the date of this Agreement, with a possible extension of three months if certain conditions are not met.",
      "categories_used": [
        "Termination  >  End Date Termination Right",
        "The Merger  >  Effective Time & Closing Process",
        "Miscellaneous  >  Legal Enforcement"
      ]
    }
  ],
  "non_solicitation": {
    "no_shop_clause": [
      {
        "section": "non_solicitation",
        "field_name": "no_shop_clause_included",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "no_shop_claus_explanation",
        "answer": "From the date of this Agreement until the earlier of the Effective Time and the termination of this Agreement in accordance with Section 7.1, except as provided in Section 5.6(b) or Section 5.6(d), (i) the Company shall, and shall cause its Subsidiaries, and its and their respective officers and directors to, immediately cease, and shall instruct and use its reasonable best efforts to cause its and their respective other Representatives to immediately cease, and cause to be terminated all existing discussions, negotiations and communications with any Persons or entities with respect to any Acquisition Proposal (other than the transactions contemplated by this Agreement), (ii) the Company shall not, and shall not authorize, and shall use its reasonable best efforts not to permit, any of its Representatives to, directly or indirectly through another Person, (A) initiate, seek, solicit, knowingly facilitate, knowingly encourage (including by way of furnishing any non-public information) or knowingly induce or knowingly take any other action which would reasonably be expected to lead to an Acquisition Proposal, (B) engage in negotiations or discussions with, or provide any non-public information or non-public data to, any Person (other than Parent or any of its Representatives) relating to or for the purpose of encouraging or facilitating, any Acquisition Proposal or grant any waiver or release under any standstill, confidentiality or other similar agreement (except that if the Company Board determines in good faith that the failure to grant any waiver or release would be inconsistent with its fiduciary duties under applicable Law, the Company may waive any such standstill provision in order to permit a third party to make and pursue an Acquisition Proposal) or (C) resolve to do any of the foregoing, (iii) the Company shall not provide and shall, within one (1) Business Day of the date of this Agreement, terminate access of any third party to any data room (virtual or actual) which has been set up in the context of a possible Acquisition Proposal containing any information of the Company or any of its Subsidiaries and (iv) within one (1) Business Day of the date of this Agreement, the Company shall demand the return or destruction of all confidential, non-public information and materials that have been provided to third parties that have entered into confidentiality agreements relating to a possible Acquisition Proposal with the Company or any of its Subsidiaries.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "notice_of_competing_offer": [
      {
        "section": "non_solicitation",
        "field_name": "notice_of_competing_offer_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "notice_of_competing_offer_explanation",
        "answer": "The Company shall (A) promptly (and in any case within twenty-four (24) hours) provide Parent notice (I) of the receipt of any Acquisition Proposal, which notice shall include a complete, unredacted copy of all written proposals, written indications of interest or draft agreements relating to, or other written materials that describe any of the material terms and conditions of, such Acquisition Proposal, and (II) of any inquiries, proposals or offers received by, any requests for non-public information from, or any discussions or negotiations initiated or continued (or sought to be initiated or continued) with, the Company or any of its Representatives concerning an Acquisition Proposal, and disclose the identity of the other party (or parties) and the material terms of such inquiry, offer, proposal or request and, in the case of written materials that describe any of the material terms and conditions of such inquiry, offer, proposal or request, provide copies of such materials.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "ongoing_update": [
      {
        "section": "non_solicitation",
        "field_name": "ongoing_update_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "ongoing_update_explanation",
        "answer": "The Company is obligated to promptly (within 24 hours) provide Parent with notice of any Acquisition Proposal, including copies of all related written materials, and keep Parent informed on a reasonably prompt basis (within 24 hours of any significant development) about the status and material details of any such proposal.",
        "confidence": 0.9,
        "reason": "The clause in Section 5.6(b) specifies that the Company must provide updates to Parent within 24 hours regarding any Acquisition Proposal and keep Parent informed of significant developments, which implies an obligation for ongoing updates.",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "superior_proposal_engagement": [
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_engagement_included",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_engagement_explanation",
        "answer": "The Company may engage with third parties if it receives a bona fide written Acquisition Proposal that was not solicited in violation of the Agreement, and the Company Board determines in good faith that such proposal constitutes or is reasonably likely to constitute a Superior Proposal, after consulting with outside financial advisors and legal counsel. This includes furnishing information and negotiating with the third party, provided a confidentiality agreement is in place and the Company Board's determination is based on fiduciary duties.",
        "confidence": 0.9,
        "reason": "The language in Section 5.6(b) allows the Company to engage with third parties if a Superior Proposal is received, based on the Company Board's good faith determination and fiduciary duties.",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "match_right": [
      {
        "section": "non_solicitation",
        "field_name": "match_right_initial_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_initial_explanation",
        "answer": "If, after the date of this Agreement and prior to the receipt of the Company Stockholder Approval, the Company Board receives a bona fide written Acquisition Proposal that the Company Board determines in good faith, after consultation with its outside financial advisors and outside legal counsel, constitutes a Superior Proposal that was not initiated, sought, solicited, knowingly facilitated, knowingly encouraged, knowingly induced or otherwise procured in violation, in any non-de minimis respect, of this Agreement, the Company Board may (i) effect an Adverse Recommendation Change or (ii) cause the Company to terminate this Agreement pursuant to Section 7.1(c)(ii) in order to enter into a definitive agreement providing for such Superior Proposal if, in each case, (A) the Company has notified Parent in writing that the Company Board intends to effect an Adverse Recommendation Change pursuant to this Section 5.6(d) or terminate this Agreement pursuant to Section 7.1(c)(ii), (B) the Company has provided Parent a copy of the proposed definitive agreements and other proposed transaction documentation between the Company and the Person making such Superior Proposal, if any, (C) for a period of four (4) Business Days following the notice delivered pursuant to clause (A) of this Section 5.6(d), the Company shall have discussed and negotiated in good faith (in each case only if Parent desires to negotiate) with Parent's Representatives any proposed modifications to the terms and conditions of this Agreement or the transactions contemplated by this Agreement so that the Acquisition Proposal is no longer a Superior Proposal (it being understood and agreed that any amendment to any material term or condition of any Superior Proposal shall require a new notice and a new negotiation period that shall expire on the later to occur of (I) two (2) Business Days following delivery of such new notice from the Company to Parent and (II) the expiration of the original four (4)-Business Day period described in this clause (C)), and (D) no earlier than the end of such negotiation period, the Company Board shall have determined in good faith, after consultation with its outside financial advisors and outside legal counsel, and after considering the terms of any proposed amendment or modification to this Agreement, that the Acquisition Proposal that is the subject of the notice described in clause (B) above still constitutes a Superior Proposal; provided that any purported termination of this Agreement pursuant to this sentence shall be void and of no force and effect unless the Company shall have paid Merger Sub (or a United States Affiliate of Merger Sub as Merger Sub may designate) the Termination Amount in accordance with Section 7.3(a) prior to or substantially concurrently with such termination.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_amended_included",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "match_right_amended_explanation",
        "answer": "If the Company Board receives a bona fide written Acquisition Proposal that constitutes a Superior Proposal, the Company must provide Parent with a new notice and a new negotiation period that shall expire on the later to occur of two (2) Business Days following delivery of such new notice from the Company to Parent and the expiration of the original four (4)-Business Day period.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "adverse_recommendation_change": [
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_superior_proposal_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_superior_proposal_explanation",
        "answer": "If, after the date of this Agreement and prior to the receipt of the Company Stockholder Approval, the Company Board receives a bona fide written Acquisition Proposal that the Company Board determines in good faith, after consultation with its outside financial advisors and outside legal counsel, constitutes a Superior Proposal that was not initiated, sought, solicited, knowingly facilitated, knowingly encouraged, knowingly induced or otherwise procured in violation, in any non-de minimis respect, of this Agreement, the Company Board may (i) effect an Adverse Recommendation Change or (ii) cause the Company to terminate this Agreement pursuant to Section 7.1(c)(ii) in order to enter into a definitive agreement providing for such Superior Proposal if, in each case, (A) the Company has notified Parent in writing that the Company Board intends to effect an Adverse Recommendation Change pursuant to this Section 5.6(d) or terminate this Agreement pursuant to Section 7.1(c)(ii), (B) the Company has provided Parent a copy of the proposed definitive agreements and other proposed transaction documentation between the Company and the Person making such Superior Proposal, if any, (C) for a period of four (4) Business Days following the notice delivered pursuant to clause (A) of this Section 5.6(d), the Company shall have discussed and negotiated in good faith (in each case only if Parent desires to negotiate) with Parent's Representatives any proposed modifications to the terms and conditions of this Agreement or the transactions contemplated by this Agreement so that the Acquisition Proposal is no longer a Superior Proposal (it being understood and agreed that any amendment to any material term or condition of any Superior Proposal shall require a new notice and a new negotiation period that shall expire on the later to occur of (I) two (2) Business Days following delivery of such new notice from the Company to Parent and (II) the expiration of the original four (4)-Business Day period described in this clause (C)), and (D) no earlier than the end of such negotiation period, the Company Board shall have determined in good faith, after consultation with its outside financial advisors and outside legal counsel, and after considering the terms of any proposed amendment or modification to this Agreement, that the Acquisition Proposal that is the subject of the notice described in clause (B) above still constitutes a Superior Proposal; provided that any purported termination of this Agreement pursuant to this sentence shall be void and of no force and effect unless the Company shall have paid Merger Sub (or a United States Affiliate of Merger Sub as Merger Sub may designate) the Termination Amount in accordance with Section 7.3(a) prior to or substantially concurrently with such termination.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_intervening_event_included",
        "answer": true,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "adverse_recommendation_change_intervening_event_explanation",
        "answer": "If, after the date of this Agreement and prior to the receipt of the Company Stockholder Approval, the Company Board may, in response to an Intervening Event, take any action prohibited by clause (i) of Section 5.6(c), only if (i) the Company Board determines in good faith, after consultation with its outside financial advisors and outside legal counsel, that the failure to take such action would be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has notified Parent in writing that the Company Board intends to effect such an Adverse Recommendation Change pursuant to this Section 5.6(e) (which notice shall specify the facts and circumstances providing the basis of the Intervening Event and for the Company Board's determination to effect such an Adverse Recommendation Change in reasonable detail), (iii) for a period of four (4) Business Days following the notice delivered pursuant to clause (ii) of this Section 5.6(e), the Company shall have discussed and negotiated in good faith (in each case only if Parent desires to negotiate) with Parent's Representatives any proposed modifications to the terms and conditions of this Agreement or the transactions contemplated by this Agreement so that the failure to take such action would no longer be inconsistent with the Company Board's fiduciary duties under applicable Law (it being understood and agreed that any material change to the relevant facts and circumstances shall require a new notice and a new negotiation period that shall expire on the later to occur of (A) two (2) Business Days following delivery of such new notice from the Company to Parent and (B) the expiration of the original four (4) Business Day period described above in this clause (iii)), and (iv) no earlier than the end of such negotiation period, the Company Board shall have determined in good faith, after consultation with its outside financial advisors and outside legal counsel, and after considering the terms of any proposed amendment or modification to this Agreement, that the failure to take such action would still be inconsistent with its fiduciary duties under applicable Law.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "go_shop": [
      {
        "section": "non_solicitation",
        "field_name": "go_shop_included",
        "answer": false,
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "go_shop_explanation",
        "answer": "Not found",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "standstill_waiver_restriction": [
      {
        "section": "non_solicitation",
        "field_name": "standstill_waiver_restriction_included",
        "answer": "false",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "standstill_waiver_restriction_explanation",
        "answer": "If the Company Board determines in good faith that the failure to grant any waiver or release would be inconsistent with its fiduciary duties under applicable Law, the Company may waive any such standstill provision in order to permit a third party to make and pursue an Acquisition Proposal.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "superior_proposal": [
      {
        "section": "non_solicitation",
        "field_name": "superior_proposal_definition",
        "answer": "Superior Proposal shall mean a bona fide written Acquisition Proposal (provided that for purposes of this definition, references to 'twenty percent (20%) or more' in the definition of 'Acquisition Proposal' shall be deemed to be references to 'more than fifty percent (50%)'), which the Company Board determines in good faith (i) to be reasonably likely to be consummated if accepted and (ii) to be more favorable to the Company's stockholders than the Merger and the other transactions contemplated by this Agreement, in each case, taking into account at the time of determination all relevant circumstances, including the various legal, financial and regulatory aspects of the proposal, all the terms and conditions of such proposal and this Agreement, and any changes to the terms of this Agreement offered by Parent in response to such Acquisition Proposal.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "buyer_diligence_access": [
      {
        "section": "non_solicitation",
        "field_name": "buyer_diligence_access_included",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "buyer_diligence_access_explanation",
        "answer": "The Company shall (A) promptly (and in any case within twenty-four (24) hours) provide Parent notice (I) of the receipt of any Acquisition Proposal, which notice shall include a complete, unredacted copy of all written proposals, written indications of interest or draft agreements relating to, or other written materials that describe any of the material terms and conditions of, such Acquisition Proposal, and (II) of any inquiries, proposals or offers received by, any requests for non-public information from, or any discussions or negotiations initiated or continued (or sought to be initiated or continued) with, the Company or any of its Representatives concerning an Acquisition Proposal, and disclose the identity of the other party (or parties) and the material terms of such inquiry, offer, proposal or request and, in the case of written materials that describe any of the material terms and conditions of such inquiry, offer, proposal or request, provide copies of such materials, (B) promptly (and in any case within twenty-four (24) hours) make available to Parent all material non-public information, including copies of all written materials relating to the Company and its Subsidiaries, made available by the Company to such party but not previously made available to Parent and (C) keep Parent informed on a reasonably prompt basis (and, in any case, within twenty-four (24) hours of any significant development) of the status and material details (including amendments and proposed amendments) of any such Acquisition Proposal or other inquiry, offer, proposal or request and providing to Parent copies of any additional or revised written proposals or written indications of interest or draft agreements relating to such Acquisition Proposal or other inquiry, offer, proposal or request, or other written materials that describe any of the material terms and conditions of such Acquisition Proposal or other inquiry, offer, proposal or request.",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ],
    "recommendation_change_restriction": [
      {
        "section": "non_solicitation",
        "field_name": "recommendation_change_restriction_included",
        "answer": "true",
        "confidence": 1.0,
        "reason": "",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      },
      {
        "section": "non_solicitation",
        "field_name": "recommendation_change_restriction_explanation",
        "answer": "The agreement imposes procedural and timing-based restrictions on how the Company may change its recommendation. Before making an Adverse Recommendation Change, the Company must notify Parent in writing of its intention, provide Parent with a copy of the proposed definitive agreements, and engage in good faith negotiations with Parent for a period of four (4) Business Days to allow Parent to propose modifications to the agreement. If there is any amendment to the Superior Proposal, a new notice and negotiation period is required. These steps must be completed before the Company Board can determine that the Acquisition Proposal still constitutes a Superior Proposal.",
        "confidence": 0.9,
        "reason": "The agreement outlines specific procedural steps and waiting periods before a recommendation change, such as notifying Parent and engaging in negotiations, which are standard in M&A agreements.",
        "categories_used": [
          "Covenants  >  Deal Protection",
          "Covenants  >  Conduct of Business",
          "Covenants  >  Notification / Publicity"
        ]
      }
    ]
  }
}
